Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.62 |
| ▸ | ECE1 | P42892 | 1/20 | 0.62 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | PTH1R | Q03431 | 7/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | CCKBR | P32239 | 1/20 | 0.56 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.55 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595296 | 0.98 | GLP1R (0.64) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL29595262 | 0.98 | GLP1R (0.64) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL29595474 | 0.98 | GLP1R (0.64) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL29595353 | 0.96 | GLP1R (0.67) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL29594176 | 0.95 | RXFP1 (0.69) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL30444117 | 0.91 | RXFP1 (0.60) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL29594804 | 0.91 | GLP1R (0.65) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL29594305 | 0.91 | GLP1R (0.68) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL30130529 | 0.90 | NPBWR1 (0.59) | GLP1RECE1MUS81RXFP1 | |
| SCHEMBL30092986 | 0.90 | NPBWR1 (0.59) | GLP1RECE1MUS81RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312756-B2 | Engineered potent cytotoxic stapled BH3 peptides | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-04-26 | — | — | US | claimed |
| US-11312756-B2 | Engineered potent cytotoxic stapled BH3 peptides | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312756-B2 | Engineered potent cytotoxic stapled BH3 peptides | BID, MCL1, BCL2L13 | GLP1R 286/4885ECE1 2486/4885MUS81 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.